ClinicalTrials.gg
RecruitingNCT07617363Updated Nov 12, 2026

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

A Phase 1 interventional study of ATRN-119 and Decitabine in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Leukemia, Myeloid, Acute by Washington University School of Medicine — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Myeloid, Acute · Washington University School of Medicine.

Planned enrollment
18th of 40
36 · median 25
Started
2026
with 1 other
Phase 1
15 of 41
1 open now
Registered
41st of 41
by date

Among the 41 studies in Leukemia, Myeloid, Acute by Washington University School of Medicine, this one is the 18th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 in phase 1, and was the 41st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 41 studies in Leukemia, Myeloid, Acute by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Leukemia, Myeloid, Acute by Washington University School of Medicine, or all of them as a file.
02

Study summary

This single-center, open-label, phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antileukemic activity of ATRN-119 (mosipasertib) alone and in combination with decitabine in patients with TP53-mutated AML or higher-risk myelodysplastic syndrome (HR-MDS). The primary objective is to identify the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE) of ATRN-119 (mosipasertib) plus decitabine. The study is based on the hypothesis that ATR inhibition with ATRN-119 (mosipasertib) will enhance sensitivity to decitabine in TP53-mutated disease, resulting in deeper and more durable clinical responses.

03

Conditions studied

  • Acute Myeloid Leukemia
  • High-risk Myelodysplastic Syndrome
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AML or higher-risk MDS (HR-MDS) according to the World Health Organization (WHO) 5th Edition or International Consensus Classification (ICC) 2022 criteria.

    • HR-MDS is defined as:

      • IPSS-R (score > 3.5) or IPSS-M (score > 0.5) OR
      • ≥ 10% bone marrow blasts
  • At least one of the following demonstrated on standard of care testing:

    • A pathogenic or likely pathogenic TP53 mutation with a VAF ≥10%
    • A TP53 or chromosome 17p deletion detected in ≥10% of cells by a cytogenetic assay
    • >20% p53-positive cells by immunohistochemistry
  • Meeting R/R disease criteria for AML or HR-MDS:

    • Patients with R/R AML must have received at least 1 prior AML-directed treatment regimen appropriate for their disease and fitness. Patients with FLT3, IDH1, IDH2, or NPM1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. In addition, patients must meet at least one of the following criteria:

      • Disease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 2 cycles of a hypomethylating agent (HMA) plus venetoclax.
      • Disease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy when venetoclax was , not tolerated, or otherwise considered clinically inappropriate.
      • First relapse with an initial remission duration \< 12 months
      • First relapse following failed salvage chemotherapy
      • Relapse after hematopoietic cell transplant
      • Second or subsequent relapse
    • Patients with R/R HR-MDS must have received at least 1 prior MDS-directed treatment regimen appropriate for their disease and fitness. Patients with IDH1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. Patients must meet at least one of the following criteria:

      • Disease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy or 2 cycles of HMA in combination with another agent, including an agent as part of a clinical trial or in routine clinical care.
      • Relapse after allogeneic hematopoietic cell transplant
      • Second or subsequent relapse
  • At least 18 years of age.
  • performance status ≤ 2
  • Adequate organ function within 28 days prior to the first dose of mosipasertib as defined below:

    • Total ≤ 2.0 x IULN; patients with known or suspected Gilbert's syndrome may have total bilirubin ≤ 3 x IULN
    • (SGOT)/ALT(SGPT) ≤ 2.5 x IULN
    • ≥ 45 mL/min/1.73 m\^2 by Cockcroft-Gault formula
  • The effects of mosipasertib and decitabine on the developing human fetus are unknown. For this reason, people of and people able to father a child must agree to use adequate prior to study entry, for the duration of study participation, and for 6 months after the last dose of mosipasertib or decitabine on study (whichever is later) for people of childbearing potential and 3 monthsafter the last dose of mosipasertib or decitabine on study (whichever is later) for people able to father a child.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Active CNS involvement by AML requiring therapeutic intervention.
  • Active (GVHD) requiring systemic therapy except for low-dose (prednisone ≤ 10 mg per day or other steroid equivalent)
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • Currently receiving any other investigational agents.
  • Concomitant systemic treatment with inhibitors of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, or MATE2-K. Patients may be eligible after a of at least 7 days or 5 half-lives, whichever is longer, prior to the first dose of ATRN-119.
  • Concomitant systemic treatment with strong inhibitors or inducers of CYP enzymes. Patients may be eligible after a washout period of 5 half-lives or 14 days (whichever is longer) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inducers, and 5 half-lives or 7 days (whichever is longer) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inhibitors.
  • A history of allergic reactions attributed to or known to compounds of similar chemical or biologic composition to mosipasertib, decitabine, or other agents used in the study.
  • Persistent interval using Fridericia's formula (QTcF) >480 msec ( v6.0 ≥ grade 2), except in patients with bundle branch block and/or ventricular paced rhythm for whom QTc cannot be reliably assessed using standard correction methods.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, disease requiring systemic therapy, symptomatic congestive heart failure, unstable angina pectoris, or clinically significant or uncontrolled cardiac arrhythmia. Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Function Classification; to be eligible for this trial, patients should be a class 2B or better.
  • Conditions that may impair oral drug administration or absorption, including inability to swallow oral medications, malabsorption syndromes, or other clinically significant gastrointestinal disorders.
  • Pregnant and/or breastfeeding. Women of must have a negative pregnancy test within 7 days of PK Run-In Day 1/Cycle 1 Day 1.
  • -infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing is not required in the absence of known history of infection.
  • Evidence of chronic virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load by PCR on suppressive therapy are eligible. HBV testing is not required in the absence of known history of infection.
  • History of virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing is not required in the absence of known history of infection.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Part A Dose Escalation Dose Level 1: ATRN-119

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 of each 28-day cycle. * Patients in Part A may (but are not required to) transition to the current dose level being evaluated in Part B (and thus receive decitabine concurrently with mosipasertib) following completion of the Cycle 1 DLT evaluation period for all patients in their assigned dose level, provided that dose level is determined to be safe. In order to transition from Part A to Part B, a patient must have persistent AML or HR-MDS (meaning they must NOT have achieved a CR without MRD) and must meet all eligibility criteria. In addition, both they and their physician must be in agreement that the decision to transition is desired and acceptable. * Patients may continue treatment for up to 24 total cycles across Parts A and B unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119

  • Experimental
    Part A Dose Escalation Dose Level 2: ATRN-119

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 of each 28-day cycle. * Patients in Part A may (but are not required to) transition to the current dose level being evaluated in Part B (and thus receive decitabine concurrently with mosipasertib) following completion of the Cycle 1 DLT evaluation period for all patients in their assigned dose level, provided that dose level is determined to be safe. In order to transition from Part A to Part B, a patient must have persistent AML or HR-MDS (meaning they must NOT have achieved a CR without MRD) and must meet all eligibility criteria. In addition, both they and their physician must be in agreement that the decision to transition is desired and acceptable. * Patients may continue treatment for up to 24 total cycles across Parts A and B unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119

  • Experimental
    Part A Dose Escalation Dose Level 3: ATRN-119

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 of each 28-day cycle. * Patients in Part A may (but are not required to) transition to the current dose level being evaluated in Part B (and thus receive decitabine concurrently with mosipasertib) following completion of the Cycle 1 DLT evaluation period for all patients in their assigned dose level, provided that dose level is determined to be safe. In order to transition from Part A to Part B, a patient must have persistent AML or HR-MDS (meaning they must NOT have achieved a CR without MRD) and must meet all eligibility criteria. In addition, both they and their physician must be in agreement that the decision to transition is desired and acceptable. * Patients may continue treatment for up to 24 total cycles across Parts A and B unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119

  • Experimental
    Part B Dose Escalation Dose Level 1: ATRN-119 + Decitabine

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 and 20 mg/m\^2 of decitabine given intravenously (IV) on Days 1-5 of each 28-day cycle. * Patients may continue treatment for up to 24 total cycles unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119 · Drug: Decitabine

  • Experimental
    Part B Dose Escalation Dose Level 2: ATRN-119 + Decitabine

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 and 20 mg/m\^2 of decitabine given intravenously (IV) on Days 1-5 of each 28-day cycle. * Patients may continue treatment for up to 24 total cycles unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119 · Drug: Decitabine

  • Experimental
    Part B Dose Escalation Dose Level 3: ATRN-119 + Decitabine

    * Patients will take ATRN-119 at the assigned dose level by mouth once per day on Days 1-28 and 20 mg/m\^2 of decitabine given intravenously (IV) on Days 1-5 of each 28-day cycle. * Patients may continue treatment for up to 24 total cycles unless disease is considered refractory after Cycle 4, or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: ATRN-119 · Drug: Decitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number and grade of treatment-emergent adverse events (TEAEs) as assessed via CTCAE v6.0 (All Patients)

    Time frame: From start of treatment until 30 days after last dose of ATRN-119 (approximately 23 months)

  2. Incidence of dose-limiting toxicities (DLTs) during Cycle 1 as assessed via CTCAE v6.0 (All Patients)

    The DLT evaluation period is 28 days from initiation of study treatment (Cycle 1), except in cases of persistent neutropenia meeting hematologic DLT criteria, for which the observation window will extend to 42 days from treatment initiation. DLTs are defined in the protocol.

    Time frame: From Cycle 1 Day 1 to end of Cycle 1 Day 28/Cycle 1 Day 42 (total time 28-42 days)

Secondary outcomes

  1. Rate of Complete Remission (CR) (All Patients)

    European LeukemiaNet (ELN) 2022 Response Criteria assesses AML and the International Working Group (IWG) 2023 Response Criteria assesses Higher-Risk MDS (HR-MDS). CR AML: Bone marrow blasts \< 5%; absence of circulating blasts; absence of extramedullary disease; ANC ≥ 1.0 x 10\^9/L (1,000/μL); platelet count ≥ 100 x 10\^9/L (100,000/μL). CR HR-MDS: Bone marrow: \< 5% myeloblasts; dysplasia may persist and peripheral blood: hemoglobin ≥ 10 g/dL, platelets ≥ 100 x 10\^9/L, neutrophils ≥ 1.0 x 10\^9/L, blasts 0%

    Time frame: Through completion of treatment (estimated total time 22 months)

  2. Rate of Complete Remission with partial hematologic recovery (CRh) (All Patients)

    European LeukemiaNet (ELN) 2022 Response Criteria assesses AML and the International Working Group (IWG) 2023 Response Criteria assesses Higher-Risk MDS (HR-MDS). CRh is defined according to the ELN 2022 Response Criteria: ANC ≥ 0.5 x 10\^9/L (500 μL) and platelet count ≥ 50 x 10\^9/L (50,000/μL), otherwise all other CR criteria met CRh is defined according to the IWG 2023 Response Criteria: Bone marrow: \< 5% myeloblasts; dysplasia may persist; Peripheral blood: not meeting criteria for CR or CRL; no hemoglobin threshold required, platelets ≥ 50 x 10\^9/L, neutrophils ≥ 0.5 x 10\^9/L, blasts 0%

    Time frame: Through completion of treatment (estimated total time 22 months)

  3. Rate of Partial Remission (PR) (All Patients)

    European LeukemiaNet (ELN) 2022 Response Criteria assesses AML and the International Working Group (IWG) 2023 Response Criteria assesses Higher-Risk MDS (HR-MDS). PR is defined according to the ELN 2022 Response Criteria: All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pre-treatment bone marrow blast percentage by at least 50% PR is defined according to the IWG 2023 Response Criteria: All CR criteria except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still ≥ 5% and Cellularity and morphology not relevant

    Time frame: Through completion of treatment (estimated total time 22 months)

  4. Duration of Response (DoR) (All Patients)

    DoR will be measured from the first documented response until earliest date of disease progression or death from any cause, as defined in the protocol or disease-specific criteria (ELN 2022 for AML and IWG 2023 for HR-MDS). DOR will be summarized among responders only. Individuals who do not exhibit any disease progression or death during the follow-up period are censored at the last date of the response assessment.

    Time frame: From first documented response until disease progression or death (up to 48 months)

  5. Event-free Survival (EFS) (All Patients)

    EFS will be measured from Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death from any cause, consistent with protocol definitions and disease-specific response criteria (ELN 2022 for AML and IWG 2023 for HR-MDS). EFS will be summarized in the efficacy-evaluable population. Participants without an event will be censored at the last disease assessment date at which they were known to be event-free.

    Time frame: From Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death (up to 48 months)

  6. Overall Survival (OS) (All Patients)

    OS will be measured from Cycle 1 Day 1 to death from any cause. Participants alive at last follow-up will be censored on the date last known alive. OS will be summarized in all treated participants.

    Time frame: From Cycle 1 Day 1 to death from any cause (up to 48 months)

  7. Rate of Complete Remission with incomplete count recovery (CRi) (AML Patients only)

    Response is assessed according to the ELN 2022 Response Criteria for AML. CRi is defined as all CR criteria except for residual neutropenia \< 1.0 x 10\^9/L (500/μL) or thrombocytopenia \< 100 x 10\^9/L (50,000/μL); CRi should only include patients not meeting the definition of CRh.

    Time frame: Through completion of treatment (estimated total time 22 months)

  8. Rate of morphologic leukemia-free state (MLFS) (AML Patients only)

    Response is assessed according to the ELN 2022 Response Criteria for AML. MLFS is defined as bone marrow blasts \< 5%; absence of circulating blasts; absence of extramedullary disease; no hematologic recovery required.

    Time frame: Through completion of treatment (estimated total time 22 months)

  9. Rate of composite Complete Remission (cCR) (AML Patients only)

    Response is assessed according to the ELN 2022 Response Criteria for AML. cCR is defined as complete remission (CR) + complete remission with partial hematologic recovery (CRh) + complete remission with incomplete hematologic recovery (CRi)

    Time frame: Through completion of treatment (estimated total time 22 months)

  10. Overall Response Rate (ORR) (AML Patients only)

    Response is assessed according to the ELN 2022 Response Criteria for AML. ORR is defined as complete remission (CR) + complete remission with partial hematologic recovery (CRh) + complete remission with incomplete hematologic recovery (CRi) + partial remission (PR) + morphologic leukemia-free state (MLFS)

    Time frame: Through completion of treatment (estimated total time 22 months)

  11. Rate of Complete Remission (CR) equivalent (HR-MDS patients only)

    CR is assessed according to the IWG 2023 Response Criteria for HR-MDS. CR: Bone marrow: \< 5% myeloblasts; dysplasia may persist; Peripheral blood: hemoglobin ≥ 10 g/dL, platelets ≥ 100 x 10\^9/L, neutrophils ≥ 1.0 x 10\^9/L, blasts 0%

    Time frame: Through completion of treatment (estimated total time 22 months)

  12. Rate of Complete Remission with limited count recovery (CRL) (HR-MDS patients only)

    CRL is assessed according to the IWG 2023 Response Criteria for HR-MDS. CRL (CRuni and CRbi): Bone marrow: \< 5% myeloblasts; dysplasia may persist; Peripheral blood: blasts 0%; Complete remission unilineage (CRuni): peripheral blood not meeting CR but only one of the following: hemoglobin ≥ 10 g/dL, platelets ≥ 100 x 10\^9/L, neutrophils ≥ 1.0 x 10\^9/L Complete remission bilineage (CRbi): peripheral blood not meeting CR but only two of the following: hemoglobin ≥ 10 g/dL, platelets ≥ 100 x 10\^9/L, neutrophils ≥ 1.0 x 10\^9/L

    Time frame: Through completion of treatment (estimated total time 22 months)

  13. Rate of Hematological Improvement (HI) (HR-MDS patients only)

    HI is assessed according to the IWG 2018 Response Criteria for HR-MDS. HI: Not meeting criteria for complete remission (CR) (or CR equivalent) or complete remission unilineage (CRuni) or complete remission with limited count recovery (CRL); HIerythroid (HI-E); HIplatelets (HI-P); HIneutrophils (HI-N).

    Time frame: Through completion of treatment (estimated total time 22 months)

  14. Rate of composite Complete Remission (cCR) (HR-MDS patients only)

    cCR is assessed according to the IWG 2023 Response Criteria for HR-MDS. cCR is defined as complete remission (CR) + complete remission (CR) equivalent + complete remission with limited count recover (CRL) + complete remission with partial hematologic recovery (CRh)

    Time frame: Through completion of treatment (estimated total time 22 months)

  15. Overall Response Rate (ORR) (HR-MDS patients only)

    Response is assessed via the IWG 2023 Response Criteria for HR-MDS. ORR is defined as complete remission (CR) + complete remission (CR) equivalent + complete remission with limited count recover (CRL) + complete remission with partial hematologic recovery (CRh) + partial remission (PR) + hematological improvement (HI)

    Time frame: Through completion of treatment (estimated total time 22 months)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Geoffrey L Uy, MD · Contactagasanli@wustl.edu · 314-747-2449
    • Geoffrey L Uy, MD · Principal investigator
    • Daniel C Link, MD · Sub investigator
    • J Scott Beeler, MD, PhD · Sub investigator
    • Fei Wan, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications arising from this study will be made available to qualified investigators.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will become available beginning 6 months after publication of the primary study results and will remain available for at least 5 years thereafter.

Access criteria: De-identified individual participant data will be made available upon reasonable request to the Principal Investigator following publication of the primary study results. Requests must include a scientifically sound proposal and may require execution of a data use agreement and approval by Washington University and other applicable oversight bodies.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2029, 35 months later.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 35 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Nov 2026, primary completion Jan 2030 → Oct 2029 and completion Dec 2031 → Nov 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 1, 2026
StartEst.
Nov 30, 2026was Aug 2026
Primary completionEst.
Oct 31, 2029was Jan 2030
CompletionEst.
Nov 30, 2031was Dec 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
Washington University School of Medicine is now Recruiting
Nov 12, 2026
Start date
Aug 31, 2026→Nov 30, 2026
Nov 2, 2026
Primary completion
Jan 31, 2030→Oct 31, 2029
Nov 2, 2026
Study completion
Dec 31, 2031→Nov 30, 2031
Nov 2, 2026
Enrollment
27→36
Nov 2, 2026
Eligibility
6 inclusion criteria edited, 17 added, 7 removed; 3 exclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedIPSS-R (score > 3.5) or IPSS-M (score > 0.5) OR ii.≥ 10% bone marrow blasts
  • RemovedDose Escalation ONLY - One of the following:
  • RemovedPreviously untreated AML with ELN 2022 adverse-risk genetic features based on local testing, in patients who are ineligible for intensive induction chemotherapy (cytarabine plus an anthracycline) due to age, comorbidities, or performance status.
  • RemovedPreviously untreated HR-MDS
  • RemovedRelapsed or refractory AML or HR-MDS meeting one or more of the following criteria: Failure to achieve CR, CRh, or CRi after ≥ 4 cycles of a hypomethylating agent (HMA); Failure to achieve CR, CRh, or CRi after ≥ 2 cycles of a HMA plus venetoclax; Overt disease progression during HMA-based therapy; First relapse with an initial remission duration < 12 months; First relapse following failed salvage chemotherapy; Relapse after allogeneic hematopoietic cell transplant; Second or subsequent relapse
  • RemovedDose Expansion ONLY - Both of the following:
  • RemovedAML or HR-MDS with a TP53 alteration, defined by the presence of any of the following features on local testing: Pathogenic or likely pathogenic TP53 mutation detected by molecular testing (with a minimum 2% VAF); Cytogenetic and/or FISH evidence of 17p deletion involving TP53 (with a minimum 2% cell involvement or the lower limit of detection of the assay); Increased hematopoietic p53 protein expression by immunohistochemistry (defined as >20% p53-positive cells). Patients enrolled during the dose expansion phase on the basis of increased p53 protein expression who are subsequently found not to harbor a TP53 mutation on molecular testing may continue study treatment.
  • RemovedNo prior therapy for a myeloid neoplasm, with the exception of permitted treatments
  • Added≥ 10% bone marrow blasts
  • AddedAt least one of the following demonstrated on standard of care testing:
  • AddedA pathogenic or likely pathogenic TP53 mutation with a VAF ≥10%
  • AddedA TP53 or chromosome 17p deletion detected in ≥10% of cells by a cytogenetic assay
  • Added>20% p53-positive cells by immunohistochemistry
  • AddedMeeting R/R disease criteria for AML or HR-MDS:
  • AddedPatients with R/R AML must have received at least 1 prior AML-directed treatment regimen appropriate for their disease and fitness. Patients with FLT3, IDH1, IDH2, or NPM1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. In addition, patients must meet at least one of the following criteria:
  • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 2 cycles of a hypomethylating agent (HMA) plus venetoclax.
  • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy when venetoclax was contraindicated, not tolerated, or otherwise considered clinically inappropriate.
  • AddedFirst relapse with an initial remission duration < 12 months
  • AddedFirst relapse following failed salvage chemotherapy
  • AddedRelapse after allogeneic hematopoietic cell transplant
  • AddedSecond or subsequent relapse
  • AddedPatients with R/R HR-MDS must have received at least 1 prior MDS-directed treatment regimen appropriate for their disease and fitness. Patients with IDH1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. Patients must meet at least one of the following criteria:
  • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy or 2 cycles of HMA in combination with another agent, including an investigational agent as part of a clinical trial or in routine clinical care.
  • AddedRelapse after allogeneic hematopoietic cell transplant
  • AddedSecond or subsequent relapse
  • EditedAdequate organ function within 28 days prior to the first dose of ATRN-119mosipasertib as defined below:
  • EditedTotal bilirubin ≤ 2.0 x IULN; patients with known or suspected Gilbert's syndrome may have total bilirubin ≤ 5 mg/dL3 x IULN
  • EditedAST(SGOT)/ALT(SGPT) ≤ 32.05 x IULN
  • ChangedBefore Estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 or creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault formula or creatinine ≤ 2.0 x IULNNow Creatinine clearance ≥ 45 mL/min/1.73 m\^2 by Cockcroft-Gault formula
  • EditedThe effects of ATRN-119mosipasertib and decitabine on the developing human fetus are unknown. For this reason, people of childbearing potential and people able to father a child must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after the last dose of ATRN-119mosipasertib or decitabine on study (whichever is later) for people of childbearing potential and 3 monthsmonthsafter the last dose of mosipasertib or decitabine on study (whichever is later) for people able to father a child.
Exclusion criteria
  • RemovedDose Expansion ONLY - Prior therapy for AML, HR-MDS, antecedent MDS, or antecedent myeloproliferative neoplasm (MPN) with the exception of erythropoiesis-stimulating agents, hematopoietic growth factors (e.g., G-CSF, thrombopoietin receptor agonists), hydroxyurea, luspatercept, imetelstat, all-trans retinoic acid (ATRA), and leukapheresis.
  • AddedConcomitant systemic treatment with inhibitors of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, or MATE2-K. Patients may be eligible after a washout period of at least 7 days or 5 half-lives, whichever is longer, prior to the first dose of ATRN-119.
  • EditedConcomitant systemic treatment with strong inhibitors or inducers of CYP3A4CYP enzymes. Patients may be eligible after a washout period of 5 half-lives or 2814 days (whichever is shorterlonger) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inducers, and 5 half-lives or 7 days (whichever is longer) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inhibitors.
  • EditedA history of allergic reactions attributed to or known hypersensitivity to compounds of similar chemical or biologic composition to ATRN-119mosipasertib, decitabine, or other agents used in the study.
  • AddedPersistent corrected QT interval using Fridericia's formula (QTcF) >480 msec (CTCAE v6.0 ≥ grade 2), except in patients with bundle branch block and/or ventricular paced rhythm for whom QTc cannot be reliably assessed using standard correction methods.
  • EditedPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of PK Run-In Day 1/Cycle 1 Day 1.
Nov 2, 2026
Interventions
Arm changed Part A Dose Escalation Dose Level 1: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 1: ATRN-119; Part A Dose Escalation Dose Level 2: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 2: ATRN-119; Part A Dose Escalation Dose Level -1: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 3: ATRN-119; Part B Dose Expansion: ATRN-119 + Decitabine→Part B Dose Escalation Dose Level 1: ATRN-119 + Decitabine. Arms added: Part B Dose Escalation Dose Level 2: ATRN-119 + Decitabine·Part B Dose Escalation Dose Level 3: ATRN-119 + Decitabine
Nov 2, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber and grade of treatment-emergent adverse events (TEAEs) as assessed via CTCAE v6.0 (All Patients)Time frame: From start of treatment until 30 days after last dose of ATRN-119 (approximately 23 months)
  • EditedIncidence of dose-limiting toxicities (DLTs) during Cycle 1 as assessed via CTCAE v6.0 (All Patients)Time frame: From Cycle 1 Day 1 to end of Cycle 1 Day 28/Cycle 1 Day 42 (total time 28-42 days)
Nov 2, 2026
Secondary outcomes
15 edited
What changed in the outcomes
  • EditedRate of Complete Remission (CR) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedRate of Complete Remission with partial hematologic recovery (CRh) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedRate of Partial Remission (PR) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedDuration of Response (DoR) (All Patients)Time frame: From first documented response until disease progression or death (up to 46 months) → From first documented response until disease progression or death (up to 48 months)
  • EditedEvent-free Survival (EFS) (All Patients)Time frame: From Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death (up to 46 months) → From Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death (up to 48 months)
  • EditedOverall Survival (OS) (All Patients)Time frame: From Cycle 1 Day 1 to death from any cause (up to 46 months) → From Cycle 1 Day 1 to death from any cause (up to 48 months)
  • EditedAML Patients only: Rate of Complete Remission with incomplete count recovery (CRi) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedAML Patients only: Rate of morphologic leukemia-free state (MLFS) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedAML Patients only: Rate of composite Complete Remission (cCR) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedAML Patients only: Overall Response Rate (ORR) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedHR-MDS patients only: Rate of Complete Remission (CR) equivalent (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedHR-MDS patients only: Rate of Complete Remission with limited count recovery (CRL) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedHR-MDS patients only: Rate of Hematological Improvement (HI) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedHR-MDS patients only: Rate of composite Complete Remission (cCR) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
  • EditedHR-MDS patients only: Overall Response Rate (ORR) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
Nov 2, 2026
Contact
Study contact's phone or email changed: •••8519→•••2449; g•••@wustl.edu→a•••@wustl.edu. See the current contact
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Washington University School of Medicine · St Louis, United StatesContact •••8519→•••2449Contact g•••@wustl.edu→a•••@wustl.edu
Nov 6, 2026
Sponsor
Collaborators added: The V Foundation for Cancer Research
Nov 2, 2026
Show all 3 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    Washington University School of Medicine is now Recruiting
  2. Nov 6, 2026
    Contact Study contact's phone or email changed: •••8519→•••2449; g•••@wustl.edu→a•••@wustl.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine · St Louis, United StatesContact •••8519→•••2449Contact g•••@wustl.edu→a•••@wustl.edu
    + 1 other change: verification date
  3. Nov 2, 2026
    Start date Aug 31, 2026→Nov 30, 2026
    Primary completion Jan 31, 2030→Oct 31, 2029
    Study completion Dec 31, 2031→Nov 30, 2031
    Enrollment 27→36
    Eligibility 6 inclusion criteria edited, 17 added, 7 removed; 3 exclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedIPSS-R (score > 3.5) or IPSS-M (score > 0.5) OR ii.≥ 10% bone marrow blasts
    • RemovedDose Escalation ONLY - One of the following:
    • RemovedPreviously untreated AML with ELN 2022 adverse-risk genetic features based on local testing, in patients who are ineligible for intensive induction chemotherapy (cytarabine plus an anthracycline) due to age, comorbidities, or performance status.
    • RemovedPreviously untreated HR-MDS
    • RemovedRelapsed or refractory AML or HR-MDS meeting one or more of the following criteria: Failure to achieve CR, CRh, or CRi after ≥ 4 cycles of a hypomethylating agent (HMA); Failure to achieve CR, CRh, or CRi after ≥ 2 cycles of a HMA plus venetoclax; Overt disease progression during HMA-based therapy; First relapse with an initial remission duration < 12 months; First relapse following failed salvage chemotherapy; Relapse after allogeneic hematopoietic cell transplant; Second or subsequent relapse
    • RemovedDose Expansion ONLY - Both of the following:
    • RemovedAML or HR-MDS with a TP53 alteration, defined by the presence of any of the following features on local testing: Pathogenic or likely pathogenic TP53 mutation detected by molecular testing (with a minimum 2% VAF); Cytogenetic and/or FISH evidence of 17p deletion involving TP53 (with a minimum 2% cell involvement or the lower limit of detection of the assay); Increased hematopoietic p53 protein expression by immunohistochemistry (defined as >20% p53-positive cells). Patients enrolled during the dose expansion phase on the basis of increased p53 protein expression who are subsequently found not to harbor a TP53 mutation on molecular testing may continue study treatment.
    • RemovedNo prior therapy for a myeloid neoplasm, with the exception of permitted treatments
    • Added≥ 10% bone marrow blasts
    • AddedAt least one of the following demonstrated on standard of care testing:
    • AddedA pathogenic or likely pathogenic TP53 mutation with a VAF ≥10%
    • AddedA TP53 or chromosome 17p deletion detected in ≥10% of cells by a cytogenetic assay
    • Added>20% p53-positive cells by immunohistochemistry
    • AddedMeeting R/R disease criteria for AML or HR-MDS:
    • AddedPatients with R/R AML must have received at least 1 prior AML-directed treatment regimen appropriate for their disease and fitness. Patients with FLT3, IDH1, IDH2, or NPM1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. In addition, patients must meet at least one of the following criteria:
    • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 2 cycles of a hypomethylating agent (HMA) plus venetoclax.
    • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy when venetoclax was contraindicated, not tolerated, or otherwise considered clinically inappropriate.
    • AddedFirst relapse with an initial remission duration < 12 months
    • AddedFirst relapse following failed salvage chemotherapy
    • AddedRelapse after allogeneic hematopoietic cell transplant
    • AddedSecond or subsequent relapse
    • AddedPatients with R/R HR-MDS must have received at least 1 prior MDS-directed treatment regimen appropriate for their disease and fitness. Patients with IDH1 mutations must also have previously received, or been deemed ineligible for, an approved targeted therapy directed against the relevant mutation. Patients must meet at least one of the following criteria:
    • AddedDisease progression during treatment with, or failure to achieve CR, CRh, or CRi after ≥ 4 cycles of HMA-based therapy or 2 cycles of HMA in combination with another agent, including an investigational agent as part of a clinical trial or in routine clinical care.
    • AddedRelapse after allogeneic hematopoietic cell transplant
    • AddedSecond or subsequent relapse
    • EditedAdequate organ function within 28 days prior to the first dose of ATRN-119mosipasertib as defined below:
    • EditedTotal bilirubin ≤ 2.0 x IULN; patients with known or suspected Gilbert's syndrome may have total bilirubin ≤ 5 mg/dL3 x IULN
    • EditedAST(SGOT)/ALT(SGPT) ≤ 32.05 x IULN
    • ChangedBefore Estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 or creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault formula or creatinine ≤ 2.0 x IULNNow Creatinine clearance ≥ 45 mL/min/1.73 m\^2 by Cockcroft-Gault formula
    • EditedThe effects of ATRN-119mosipasertib and decitabine on the developing human fetus are unknown. For this reason, people of childbearing potential and people able to father a child must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after the last dose of ATRN-119mosipasertib or decitabine on study (whichever is later) for people of childbearing potential and 3 monthsmonthsafter the last dose of mosipasertib or decitabine on study (whichever is later) for people able to father a child.
    Exclusion criteria
    • RemovedDose Expansion ONLY - Prior therapy for AML, HR-MDS, antecedent MDS, or antecedent myeloproliferative neoplasm (MPN) with the exception of erythropoiesis-stimulating agents, hematopoietic growth factors (e.g., G-CSF, thrombopoietin receptor agonists), hydroxyurea, luspatercept, imetelstat, all-trans retinoic acid (ATRA), and leukapheresis.
    • AddedConcomitant systemic treatment with inhibitors of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, or MATE2-K. Patients may be eligible after a washout period of at least 7 days or 5 half-lives, whichever is longer, prior to the first dose of ATRN-119.
    • EditedConcomitant systemic treatment with strong inhibitors or inducers of CYP3A4CYP enzymes. Patients may be eligible after a washout period of 5 half-lives or 2814 days (whichever is shorterlonger) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inducers, and 5 half-lives or 7 days (whichever is longer) before PK Run-In Day 1 or C1D1 (whichever is applicable) for strong inhibitors.
    • EditedA history of allergic reactions attributed to or known hypersensitivity to compounds of similar chemical or biologic composition to ATRN-119mosipasertib, decitabine, or other agents used in the study.
    • AddedPersistent corrected QT interval using Fridericia's formula (QTcF) >480 msec (CTCAE v6.0 ≥ grade 2), except in patients with bundle branch block and/or ventricular paced rhythm for whom QTc cannot be reliably assessed using standard correction methods.
    • EditedPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of PK Run-In Day 1/Cycle 1 Day 1.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber and grade of treatment-emergent adverse events (TEAEs) as assessed via CTCAE v6.0 (All Patients)Time frame: From start of treatment until 30 days after last dose of ATRN-119 (approximately 23 months)
    • EditedIncidence of dose-limiting toxicities (DLTs) during Cycle 1 as assessed via CTCAE v6.0 (All Patients)Time frame: From Cycle 1 Day 1 to end of Cycle 1 Day 28/Cycle 1 Day 42 (total time 28-42 days)
    Secondary outcomes 15 edited
    What changed in the outcomes
    • EditedRate of Complete Remission (CR) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedRate of Complete Remission with partial hematologic recovery (CRh) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedRate of Partial Remission (PR) (All Patients)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedDuration of Response (DoR) (All Patients)Time frame: From first documented response until disease progression or death (up to 46 months) → From first documented response until disease progression or death (up to 48 months)
    • EditedEvent-free Survival (EFS) (All Patients)Time frame: From Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death (up to 46 months) → From Cycle 1 Day 1 to treatment failure, relapse after response, progression, or death (up to 48 months)
    • EditedOverall Survival (OS) (All Patients)Time frame: From Cycle 1 Day 1 to death from any cause (up to 46 months) → From Cycle 1 Day 1 to death from any cause (up to 48 months)
    • EditedAML Patients only: Rate of Complete Remission with incomplete count recovery (CRi) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedAML Patients only: Rate of morphologic leukemia-free state (MLFS) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedAML Patients only: Rate of composite Complete Remission (cCR) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedAML Patients only: Overall Response Rate (ORR) (AML Patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedHR-MDS patients only: Rate of Complete Remission (CR) equivalent (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedHR-MDS patients only: Rate of Complete Remission with limited count recovery (CRL) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedHR-MDS patients only: Rate of Hematological Improvement (HI) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedHR-MDS patients only: Rate of composite Complete Remission (cCR) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    • EditedHR-MDS patients only: Overall Response Rate (ORR) (HR-MDS patients only)Time frame: Through completion of treatment (estimated total time 22 months)
    Interventions Arm changed Part A Dose Escalation Dose Level 1: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 1: ATRN-119; Part A Dose Escalation Dose Level 2: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 2: ATRN-119; Part A Dose Escalation Dose Level -1: ATRN-119 + Decitabine→Part A Dose Escalation Dose Level 3: ATRN-119; Part B Dose Expansion: ATRN-119 + Decitabine→Part B Dose Escalation Dose Level 1: ATRN-119 + Decitabine. Arms added: Part B Dose Escalation Dose Level 2: ATRN-119 + Decitabine·Part B Dose Escalation Dose Level 3: ATRN-119 + Decitabine
    Sponsor Collaborators added: The V Foundation for Cancer Research
    + 4 other changes: identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07617363
Collaborators
Aprea Therapeutics, National Cancer Institute (NCI), The V Foundation for Cancer Research
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Oct 31, 2029 (estimated)
Completion
Nov 30, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Geoffrey L Uy, MD
Contact
agasanli@wustl.edu
314-747-2449
Geoffrey L Uy, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATR Inhibitor ATRN-119

Start the discussion